Bioavailability and Why the Route of Administration Matters

Bioavailability is a foundational concept in pharmacology that describes how much of an active pharmaceutical ingredient actually reaches the body's systemic circulation in an active form. When a person takes a medicine, the dose printed on the packet is not always the exact amount that the body utilises. The way a medicine is introduced into the body—its route of administration—plays a major role in determining how much of that medicine eventually reaches its intended target. Understanding bioavailability helps explain why some medicines are given as tablets while others must be injected, and why different forms of the same medicine cannot always be freely substituted.

What is Bioavailability?

Bioavailability refers to the proportion of a medicine's active ingredient that successfully reaches the bloodstream and is available to produce a therapeutic effect. When a medicine is given intravenously (directly into a vein), it is placed straight into the circulation, meaning its bioavailability is generally considered to be 100 per cent. For other routes, such as oral tablets, the bioavailability is usually lower. The body naturally breaks down and filters substances as they travel from the point of entry to the systemic circulation. This is an important consideration during drug development, as manufacturers must ensure that the given dose provides a predictable and therapeutic amount of the active ingredient. If a medicine has very low oral bioavailability, alternative routes of administration may be required to ensure enough of the active ingredient reaches the body.

First-Pass Metabolism Explained

One of the main reasons oral medicines have reduced bioavailability is a biological process known as first-pass metabolism, sometimes called the first-pass effect. When a tablet or capsule is swallowed, it is absorbed through the lining of the gastrointestinal tract and enters the portal vein, which carries it directly to the liver. The liver's primary function is to filter toxins and metabolise substances, including many pharmaceutical compounds. Before the active ingredient ever reaches the rest of the body via the general circulation, a significant portion of it may be broken down by enzymes in the liver or the cells of the gut wall.

Because of this natural filtering, oral doses often need to be higher than the equivalent intravenous dose to account for the fraction lost to first-pass metabolism. Some medicines are extensively metabolised during this first pass, making oral administration impractical for certain active ingredients. In these cases, manufacturers generally develop alternative formulations, such as sublingual tablets that dissolve under the tongue and enter the bloodstream directly, bypassing the liver entirely.

Comparing Routes of Administration

Different routes of administration bypass or utilise these natural bodily filters in distinct ways. Intravenous (IV) administration bypasses the digestive system and liver entirely, making the dose highly predictable, though it is also the most invasive route and requires professional administration. Oral administration is convenient, non-invasive, and generally safe, but it is subject to first-pass metabolism and variations in absorption caused by food in the stomach or individual gut health.

Topical administration, which includes creams, ointments, and patches, is often used when a local effect is desired, such as treating a skin condition. While some topical medicines do enter the systemic circulation, they often do so slowly, and their bioavailability is generally lower and harder to predict than oral or IV forms. Similarly, inhaled medicines deliver active ingredients directly to the lungs, achieving a local effect while largely avoiding first-pass metabolism, which is why many respiratory medicines are administered this way.

Bioequivalence and Generic Medicines

The concept of bioavailability is central to the approval of generic medicines. When a patent expires on an originator medicine, other manufacturers can produce generic versions. To be approved by regulators like the South African Health Products Regulatory Authority (SAHPRA), the US Food and Drug Administration (FDA), or the European Medicines Agency (EMA), a generic must demonstrate bioequivalence. This means the generic must deliver the same amount of active ingredient into the bloodstream at the same rate as the originator product.

Regulators measure this by comparing the peak concentration of the medicine in the blood and the total exposure over time. If two medicines have the same active ingredient but significantly different bioavailability, they cannot be considered true therapeutic equivalents, and switching between them could alter how the body responds. Bioequivalence studies ensure that a generic medicine will behave in the body in a way that matches the original product.

Registration and Practical Searches

Because the route of administration directly affects bioavailability, medicines are strictly licensed and registered by their specific dosage form. A regulator will not automatically approve a switch from an oral tablet to a topical cream or an intravenous injection without separate clinical justification and safety reviews. The specific formulation, whether it is a slow-release capsule or a rapid-dissolving tablet, dictates how the medicine is absorbed. In South Africa, SAHPRA maintains records of all approved dosage forms and their specific Single Exit Price. Patients and healthcare professionals can use HealthSA to search for the registration details and pricing of specific formulations, ensuring they are looking at the correct, registered product for a given route of administration and confirming the regulatory status of the medicine.